title: Hospital in the home (HITH) care following autologous stem cell transplantation for lymphoma and multiple myeloma.
abstract: BACKGROUND
  Advances in outpatient and supportive care and increased pressure on hospital bed usage has led to the investigation of hospital in the home (HITH) management following autologous haematologous stem cell transplantation (AutoHSCT) for patients with multiple myeloma or lymphoma.
  
  
  METHODS
  The Newcastle Mater Hospital Haematology Unit together with the Mater Acute Care Community Service (MACCS) developed a protocol for HITH care following AutoHSCT.
  
  
  RESULTS
  Clinical outcomes of the protocol were audited: 40% (13) of patients were suitable candidates for HITH care post transplantation. Of these 84.6% (11) were readmitted to the haematology unit within seven days of discharge from hospital.
  
  
  CONCLUSIONS
  Our preliminary experience suggests that with adequate infrastructure support and rigorous patient selection this model of care is both safe and feasible.
authors.affiliation: Mater Acute Care Community Service, Newcastle Mater Hospital, New South Wales, Australia.
authors.forename: Wendy
authors.initials: W
authors.lastname: Johnson
authors.forename: Ian
authors.initials: I
authors.lastname: Kerridge
authors.forename: Cathie
authors.initials: C
authors.lastname: Milton
authors.forename: Debbie
authors.initials: D
authors.lastname: Carr
authors.forename: Arno
authors.initials: A
authors.lastname: Enno
authors.forename: Louisa
authors.initials: L
authors.lastname: Bray
authors.forename: Angela
authors.initials: A
authors.lastname: Booth
mesh_terms: D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols; D002985:Clinical Protocols; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D018575:Home Care Services, Hospital-Based / Q000592:standards*; D006801:Humans; D008130:Lomustine / Q000008:administration & dosage; D008223:Lymphoma / Q000601:surgery*; D008297:Male; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D009101:Multiple Myeloma / Q000601:surgery*; D009517:New South Wales; D009731:Nursing Audit; D010043:Outcome and Process Assessment, Health Care; D010359:Patient Readmission; D033581:Stem Cell Transplantation / Q000451:nursing*; D019172:Transplantation Conditioning / Q000379:methods; D014182:Transplantation, Autologous
chemical_list: D000964:Antimetabolites, Antineoplastic; D018906:Antineoplastic Agents, Alkylating; D000972:Antineoplastic Agents, Phytogenic; D003561:Cytarabine; D005047:Etoposide; D008130:Lomustine; D003520:Cyclophosphamide; D008558:Melphalan